Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM C NABOURS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1659371193
CMS profile
347673
Location
LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,779.64

119 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,779.64 119

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM C NABOURS

NPI 1659371193 · CMS profile ID 347673

Allopathic & Osteopathic Physicians / Family Medicine

LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659371193?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM C NABOURS, NPI 1659371193, CMS profile ID 347673. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659371193?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). WILLIAM C NABOURS, NPI 1659371193, CMS profile ID 347673. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659371193?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
WILLIAM C NABOURS, NPI 1659371193, CMS profile ID 347673, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659371193?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

119 matching records · $1,779.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 119 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 119.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $22.2106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811387141 CMS
SANOFI-AVENTIS U.S. LLC $14.6206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843414555 CMS
ARBOR PHARMACEUTICALS, INC. $12.0606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830943581 CMS
Esperion Therapeutics, Inc. $16.1406/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360185 CMS
AbbVie Inc. $27.8106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268949 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.4506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763427162 CMS
Amgen Inc. $7.6906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825869805 CMS
Astellas Pharma US Inc $16.6106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821463979 CMS
Amgen Inc. $6.4206/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826455569 CMS
AstraZeneca Pharmaceuticals LP $13.0206/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829614309 CMS
Novo Nordisk Inc $15.6106/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810715951 CMS
Merck Sharp & Dohme Corporation $17.3106/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848333163 CMS
Lilly USA, LLC $11.1605/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818815459 CMS
SANOFI-AVENTIS U.S. LLC $14.5705/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843414523 CMS
Novo Nordisk Inc $7.1805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811387137 CMS
AbbVie Inc. $27.2905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268943 CMS
Lilly USA, LLC $15.7605/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818779511 CMS
Esperion Therapeutics, Inc. $19.1005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360183 CMS
Novo Nordisk Inc $12.6205/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811746701 CMS
AbbVie Inc. $11.2305/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268935 CMS
Astellas Pharma US Inc $13.5504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821463973 CMS
Amgen Inc. $11.3004/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825869801 CMS
Biohaven Pharmaceuticals, Inc. $19.3104/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852573847 CMS
Lilly USA, LLC $13.6804/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818767775 CMS
Merck Sharp & Dohme Corporation $13.4704/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848328531 CMS
Novo Nordisk Inc $7.8304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811746699 CMS
AbbVie Inc. $18.6004/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268929 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.0404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763427164 CMS
AbbVie Inc. $7.9304/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268923 CMS
Novo Nordisk Inc $10.9704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811658825 CMS
Esperion Therapeutics, Inc. $17.9304/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360179 CMS
PFIZER INC. $12.7704/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833537245 CMS
Merck Sharp & Dohme Corporation $15.8003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848322075 CMS
AbbVie Inc. $17.2803/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268911 CMS
AbbVie Inc. $4.5003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268917 CMS
Lilly USA, LLC $10.5103/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818823871 CMS
AbbVie Inc. $10.9103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268905 CMS
Novo Nordisk Inc $12.4403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811387131 CMS
Amarin Pharma Inc. $18.7703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815349097 CMS
GlaxoSmithKline, LLC. $15.1003/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802685929 CMS
Amgen Inc. $15.9803/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825869825 CMS
Lilly USA, LLC $18.1003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818823307 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.9803/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820104115 CMS
Amarin Pharma Inc. $26.8403/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815251093 CMS
AbbVie Inc. $6.8203/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268899 CMS
AbbVie Inc. $4.9403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268893 CMS
GlaxoSmithKline, LLC. $15.4503/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802466365 CMS
AbbVie Inc. $8.0403/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795268887 CMS
Esperion Therapeutics, Inc. $16.1403/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360177 CMS
AstraZeneca Pharmaceuticals LP $12.4103/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829681017 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,737.09 126
PY2020 $1,264.35 80
PY2021 $1,779.64 119
PY2022 $2,046.78 128
PY2023 $740.67 42
PY2024 $97.98 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,118,331.43 11
PY2024 Recipient $173,371.00 3
PY2024 Principal investigator $857,135.62 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,400.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185545525
Principal investigator 1 Eli Lilly and Company $158,454.57 08/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187883342
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,452.80 08/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185545523
Principal investigator 1 Eli Lilly and Company $2.13 06/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF SWLA LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187879501
Principal investigator 1 Eli Lilly and Company $824,804.85 04/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187877351
Principal investigator 1 Eli Lilly and Company $621.22 01/31/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187876497
Principal investigator 1 Eli Lilly and Company $10,157.85 01/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187875459
Principal investigator 1 Eli Lilly and Company $3,065.01 01/26/2025 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A PHASE 3B, RANDOMIZED, DOUBLE-BLINDED, PLACEBO- CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY (TRIUMPH-6) No dispute reported 06/30/2026 1187892024
Principal investigator 1 Eli Lilly and Company $506,057.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187875455
Principal investigator 1 Eli Lilly and Company $522,872.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187876737
Principal investigator 1 Eli Lilly and Company $47,444.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187878279